Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue-exposed individuals

Journal of Infectious Diseases

Volumn 215, Issue 3, 2017, Pages 351-358

  Henein, Sandra ^a   Swanstrom, Jesica ^b   Byers, Anthony M ^c   Moser, Janice M ^c   Shaik, S Farzana ^c   Bonaparte, Matthew ^c   Jackson, Nicholas ^c   Guy, Bruno ^c   Baric, Ralph ^a,b   De Silva, Aravinda M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c SANOFI PASTEUR   (France)

Author keywords

Dengue vaccine; Flavivirus; Live attenuated vaccine; Neutralizing antibody

Indexed keywords

CROSS REACTING ANTIBODY; DENGUE VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DRUG EFFICACY; FLAVIVIRUS; HUMAN; HUMAN CELL; IMMUNE STATUS; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; BLOOD; CELL LINE; CLINICAL TRIAL; IMMUNOLOGY; VACCINE IMMUNOGENICITY;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; DENGUE; DENGUE VACCINES; FLAVIVIRUS; HUMANS; IMMUNOGENICITY, VACCINE; VACCINES, ATTENUATED;

EID: 85019896009     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw576     Document Type: Article

References (34)

1. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004; 10:S98-109.
2. Capeding MR, Tran NH, Hadinegoro SR, et al; CYD14 Study Group. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014; 384:1358-65.
3. Villar L, Dayan GH, Arredondo-Garcia JL, et al; CYD15 Study Group. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015; 372:113-23.
4. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559-67.
5. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al; CYD-TDV Dengue Vaccine Working Group. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015; 373:1195-206.
6. Guy B, Briand O, Lang J, Saville M, Jackson N. Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. Vaccine 2015; 33:7100-11.
7. Thomas SJ. Developing a dengue vaccine: progress and future challenges. Ann N Y Acad Sci 2014; 1323:140-59.
8. Roehrig JT. Antigenic structure of flavivirus proteins. Adv Virus Res 2003; 59:141-75.
9. Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 2003; 100:6986-91.
10. Modis Y, Ogata S, Clements D, Harrison SC. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 2005; 79:1223-31.
11. Nybakken GE, Nelson CA, Chen BR, Diamond MS, Fremont DH. Crystal structure of the West Nile virus envelope glycoprotein. J Virol 2006; 80:11467-74.
12. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 1995; 375:291-8.
13. Kuhn RJ, Zhang W, Rossmann MG, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002; 108:717-25.
14. Rothman AL. Immunology and immunopathogenesis of dengue disease. Adv Virus Res 2003; 60:397-419.
15. Wahala WMPB, de Silva AM. The human antibody response to dengue virus infection. Viruses 2011; 3:2374-95.
16. de Alwis R, Smith SA, Olivarez NP, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 2012; 109:7439-44.
17. Fibriansah G, Ibarra KD, Ng TS, et al. Dengue virus: cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 2015; 349:88-91.
18. Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 2015; 520:109-13.
19. Dejnirattisai W, Wongwiwat W, Supasa S, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 2015; 16:170-7.
20. Fibriansah G, Tan JL, Smith SA, et al. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med 2014; 6:358-71.
21. Fibriansah G, Tan JL, Smith SA, et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun 2015; 6:6341.
22. Kaufmann B, Vogt MR, Goudsmit J, et al. Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci U S A 2010; 107:18950-5.
23. Teoh EP, Kukkaro P, Teo EW, et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 2012; 4:139ra83.
24. Olkowski S, Forshey BM, Morrison AC, et al. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis 2013; 208:1026-33.
25. Torresi J, Heron LG, Qiao M, et al. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study. Vaccine 2015; 33:5127-34.
26. Dayan GH, Garbes P, Noriega F, et al. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil. Am J Trop Med Hyg 2013; 89:1058-65.
27. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain IIIreactive antibody. Virology 2009; 392:103-13.
28. Timiryasova TM, Bonaparte MI, Luo P, Zedar R, Hu BT, Hildreth SW. Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg 2013; 88:962-70.
29. Kraus AA, Messer W, Haymore LB, de Silva AM. Comparison of plaque-and flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol 2007; 45:3777-80.
30. Jackson N, Boaz M, Hu BT, Langevin E, Byers A. Investigations of the observed efficacy of the CYD tetravalent dengue vaccine in the phase 2b trial in Ratchaburi, Thailand. Am J Trop Med Hyg 2014; 91:149.
31. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010; 201:370-7.
32. Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan G. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 2011; 30:e9-17.
33. Gallichotte EN, Widman DG, Yount BL, et al. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. mBio 2015; 2015; 6:e01461-15.
34. Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol 2016; 14:45-54.